125 related articles for article (PubMed ID: 15963359)
1. Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization.
Kran AM; Sommerfelt MA; Sørensen B; Nyhus J; Baksaas I; Bruun JN; Kvale D
Vaccine; 2005 Jul; 23(31):4011-5. PubMed ID: 15963359
[TBL] [Abstract][Full Text] [Related]
2. Delayed-type hypersensitivity responses to HIV Gag p24 relate to clinical outcome after peptide-based therapeutic immunization for chronic HIV infection.
Kran AM; Sommerfelt MA; Baksaas I; Sørensen B; Kvale D
APMIS; 2012 Mar; 120(3):204-9. PubMed ID: 22339677
[TBL] [Abstract][Full Text] [Related]
3. Multiple antigen concentrations in delayed-type hypersensitivity (DTH) and response diversity during and after immunization with a peptide-based HIV-1 immunotherapy candidate (Vacc-4x).
Nyhus J; Kran AM; Sommerfelt MA; Baksaas I; Sørensen B; Kvale D
Vaccine; 2006 Mar; 24(10):1543-50. PubMed ID: 16289707
[TBL] [Abstract][Full Text] [Related]
4. Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells.
Kran AM; Sørensen B; Sommerfelt MA; Nyhus J; Baksaas I; Kvale D
AIDS; 2006 Feb; 20(4):627-30. PubMed ID: 16470131
[TBL] [Abstract][Full Text] [Related]
5. Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4 + and CD8 + T cell responses lasting more than seven years.
Lind A; Sommerfelt M; Holmberg JO; Baksaas I; Sørensen B; Kvale D
Scand J Infect Dis; 2012 Aug; 44(8):566-72. PubMed ID: 22339485
[TBL] [Abstract][Full Text] [Related]
6. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
7. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
9. Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection.
Jones T
Curr Opin Investig Drugs; 2010 Aug; 11(8):964-70. PubMed ID: 20721838
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of proliferative responses to HIV-1 antigen in chronically HIV-infected patients under antiretroviral therapy.
Mohm JM; Rump JA; Schulte-Mönting J; Schneider J
J Clin Virol; 2004 Jul; 30(3):239-42. PubMed ID: 15135742
[TBL] [Abstract][Full Text] [Related]
11. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.
Ide F; Nakamura T; Tomizawa M; Kawana-Tachikawa A; Odawara T; Hosoya N; Iwamoto A
J Med Virol; 2006 Jun; 78(6):711-8. PubMed ID: 16628588
[TBL] [Abstract][Full Text] [Related]
12. Divergent in vitro and in vivo correlates of HIV-specific T-cell responses during onset of HIV viraemia.
Kvale D; Kran AM; Sommerfelt MA; Nyhus J; Baksaas I; Bruun JN; Sørensen B
AIDS; 2005 Mar; 19(6):563-7. PubMed ID: 15802974
[TBL] [Abstract][Full Text] [Related]
13. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy.
Asjö B; Stavang H; Sørensen B; Baksaas I; Nyhus J; Langeland N
AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1357-65. PubMed ID: 12487807
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy.
Bisson GP; Gross R; Strom JB; Rollins C; Bellamy S; Weinstein R; Friedman H; Dickinson D; Frank I; Strom BL; Gaolathe T; Ndwapi N
AIDS; 2006 Aug; 20(12):1613-9. PubMed ID: 16868442
[TBL] [Abstract][Full Text] [Related]
16. Optimized virus disruption improves detection of HIV-1 p24 in particles and uncovers a p24 reactivity in patients with undetectable HIV-1 RNA under long-term HAART.
Schüpbach J; Tomasik Z; Knuchel M; Opravil M; Günthard HF; Nadal D; Böni J; ;
J Med Virol; 2006 Aug; 78(8):1003-10. PubMed ID: 16789014
[TBL] [Abstract][Full Text] [Related]
17. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
18. Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides.
Kran AM; Jonassen TO; Sommerfelt MA; Løvgården G; Sørensen B; Kvale D
AIDS; 2010 Nov; 24(17):2609-18. PubMed ID: 20935558
[TBL] [Abstract][Full Text] [Related]
19. Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART.
Jones LE; Perelson AS
Bull Math Biol; 2005 Nov; 67(6):1227-51. PubMed ID: 16023709
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
Ruiz L; Paredes R; Gómez G; Romeu J; Domingo P; Pérez-Alvarez N; Tambussi G; Llibre JM; Martínez-Picado J; Vidal F; Fumaz CR; Clotet B;
AIDS; 2007 Jan; 21(2):169-78. PubMed ID: 17197807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
